Assist. Prof. Dr. Yuming Jiang | AI in Healthcare | Best Researcher Award

Assistant Professor of Radiation Oncology at Wake Forest University School of Medicine, United States

Dr. Yuming Jiang, MD, PhD, is an Assistant Professor in the Department of Radiation Oncology at Wake Forest University School of Medicine, North Carolina, USA. His research and clinical expertise focus on the integration of artificial intelligence and digital pathology to improve cancer prognosis and treatment strategies. With a strong background in oncology and computational medicine, Dr. Jiang has made significant contributions to the understanding of tumor microenvironments and the application of deep learning in radiomics.

Profile

Google Scholar

Education

Dr. Jiang obtained his MD and PhD degrees from prestigious institutions, demonstrating a commitment to both clinical practice and scientific research. He completed his PhD in oncology at a leading university in China, followed by a postdoctoral fellowship at Stanford University from 2018 to 2023. In August 2023, he joined Wake Forest University School of Medicine as an Assistant Professor, where he continues to advance the field of radiation oncology through innovative research and patient-centered care.

Experience

Dr. Jiang has a diverse professional background that spans clinical medicine, academic research, and technological innovation. Before joining Wake Forest University, he worked as a Postdoctoral Research Fellow at Stanford University, where he contributed to groundbreaking studies on digital pathology, cancer immunotherapy, and noninvasive imaging techniques. His expertise in artificial intelligence and machine learning has enabled him to develop predictive models for cancer prognosis, treatment response, and survival outcomes.

Research Interests

Dr. Jiang’s research is centered on the intersection of oncology and artificial intelligence. His key interests include deep learning-based radiomics, tumor microenvironment analysis, and predictive modeling for personalized cancer treatment. He aims to harness computational tools to enhance diagnostic accuracy and therapeutic decision-making in radiation oncology. His work has had a profound impact on the understanding of tumor biology and has paved the way for more effective, individualized treatment strategies.

Awards

Dr. Jiang has been recognized for his contributions to oncology and medical research with several prestigious awards. His research has received accolades from leading medical societies and journals, highlighting his role in advancing cancer diagnostics and treatment methodologies. His innovative work in AI-driven oncology has earned him invitations to speak at international conferences and collaborate with esteemed institutions worldwide.

Publications

Jiang Y, Zhang Z, Wang W, Huang W, et al. “Biology-guided deep learning predicts prognosis and cancer immunotherapy response.” Nature Communications, 2023; 14: 5135. (Cited by 16.6)

Jiang Y, Zhou K, Sun Z, Wang H, et al. “Non-invasive tumor microenvironment evaluation using deep learning radiomics.” Cell Reports Medicine, 2023; 4:101146. (Cited by 14.3)

Jiang Y, Zhang Z, Yuan Q, Wang W, et al. “Predicting peritoneal recurrence from CT images using multi-task deep learning.” Lancet Digital Health, 2022; 4(5): e340-e350. (Cited by 36.6)

Jiang Y, Li R, Li G. “Artificial intelligence for clinical oncology: current status and future outlook.” Science Bulletin, 2023; (23): 00113-5. (Cited by 18.9)

Jiang Y, Liang X, Wang W, Chen C, et al. “Radiographical assessment of tumor stroma and treatment outcomes using deep learning.” Lancet Digital Health, 2021; 3(6): e371-e382. (Cited by 36.6)

Jiang Y, Jin C, Yu H, Wu J, et al. “Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer.” Annals of Surgery, 2021; 274(6): e1153-e1161. (Cited by 13.8)

Jiang Y, Wang H, Wu J, Chen C, et al. “Noninvasive imaging evaluation of tumor immune microenvironment in gastric cancer.” Annals of Oncology, 2020; 31(6): 760-768. (Cited by 32.9)

Conclusion

Dr. Yuming Jiang is at the forefront of integrating artificial intelligence into oncology, bringing innovative solutions to cancer diagnosis and treatment. His expertise in deep learning, radiomics, and tumor microenvironment studies has significantly advanced the field of radiation oncology. With a strong research background and a commitment to improving patient outcomes, Dr. Jiang continues to contribute to the medical community through his pioneering work in AI-driven cancer diagnostics and therapy.

Mr. Peng YU | AI in Healthcare | Best Researcher Award

Associate Senior Doctor at The Second Affiliated Hospital of Nanchang University, China

Dr. Peng Yu is an Associate Senior Doctor in the Department of Endocrinology & Metabolism at The Second Affiliated Hospital of Nanchang University. With a strong background in medicine and extensive experience in both clinical and academic settings, he has made significant contributions to the study of endocrinology, metabolism, and cardiovascular diseases. His research spans various areas, including diabetes, cardiovascular health, and molecular mechanisms of metabolic disorders. In addition to his role as a clinician, he is an active researcher, reviewer for several prestigious international journals, and a recipient of multiple awards recognizing his contributions to medical science.

Profile

Scopus

Education

Dr. Yu earned his Ph.D. in Medicine from Nanchang University in 2017 and previously obtained a Master’s degree in Medicine from Nanjing Medical University in 2014. His academic journey has provided him with in-depth expertise in internal medicine, cardiology, and metabolic disorders. Furthering his research career, he completed a fellowship at Massachusetts General Hospital, Harvard Medical School, focusing on cutting-edge research in CCP medicine. His multidisciplinary education has allowed him to integrate clinical expertise with molecular and cellular research, contributing to advancements in the field of endocrinology and metabolism.

Experience

Dr. Yu has held various roles in the medical field, beginning as a Resident Doctor at The Second Affiliated Hospital of Nanchang University from 2017 to 2019. He was later promoted to Attending Doctor, serving from 2019 to 2021. Since 2021, he has been an Associate Senior Doctor at the same institution, where he continues to provide expert medical care, mentor students, and engage in research activities. His collaborations with prominent researchers, including those at Harvard Medical School and Jilin University, have enriched his expertise and research output. His involvement in over 60 research projects, including several funded by the National Natural Science Foundation of China, highlights his leadership in medical research.

Research Interests

Dr. Yu’s research primarily focuses on endocrinology and metabolism, with particular emphasis on diabetes, cardiovascular diseases, and the molecular mechanisms underlying metabolic disorders. His expertise extends to mitochondrial function, oxidative stress, and the role of programmed cell death in disease progression. Utilizing various research methodologies, including confocal microscopy, Seahorse metabolic analysis, and in vivo disease modeling, he has contributed to the understanding of metabolic disorders at both cellular and systemic levels. His work also explores novel therapeutic targets for diabetic cardiomyopathy and myocardial ischemia-reperfusion injury, positioning him at the forefront of translational medicine in this domain.

Awards

Dr. Yu has been recognized for his contributions to medical research with multiple awards, including:

• Jiangxi Provincial Science and Technology Progress Third Prize (2019)
• The Third Prize of Medical Science and Technology of Jiangsu Province (2019, 2023)
• Young Innovative Talent Award, The Second Affiliated Hospital of Nanchang University (2023)

His achievements underscore his commitment to advancing medical knowledge and improving clinical outcomes in endocrinology and metabolism.

Publications

Dr. Yu has published extensively, with over 150 academic papers, including more than 100 SCI-indexed publications. His recent notable works include:

Yu P et al. “Comprehensive exploration of programmed cell death landscape in lung adenocarcinoma combining multi-omic analysis and experimental verification.” Sci Rep. 2025; 15(1):5364.

Yu P et al. “Performance of ChatGPT on the Chinese Postgraduate Examination for Clinical Medicine: Survey Study.” JMIR Med Educ. 2024; 10:e48514.

Zhao H, Li X, Yu P et al. “Association between weight loss and outcomes in patients undergoing atrial fibrillation ablation: A systematic review and meta-analysis.” Nutr Metab (Lond). 2023; 20(1):5.

Yu P et al. “Obesity and clinical outcomes in COVID-19 patients without comorbidities.” Front Endocrinol. 2022; 13:936976.

Yu P et al. “Dexmedetomidine post-conditioning alleviates myocardial ischemia-reperfusion injury in rats by ferroptosis inhibition via SLC7A11/GPX4 axis activation.” Hum Cell. 2022; 35(3):836-848.

Peng Y et al. “The Association of Serum IL-10 Levels with the Disease Activity in Systemic-Onset Juvenile Idiopathic Arthritis Patients.” Mediators Inflamm. 2021; 2021:6650928.

Conclusion

Dr. Peng Yu is a distinguished clinician and researcher specializing in endocrinology and metabolism. His contributions to the field through extensive research, innovative approaches to disease treatment, and active mentorship have positioned him as a leading expert in his domain. With numerous research grants, impactful publications, and prestigious awards, he continues to drive advancements in medical science. His work not only enhances the understanding of metabolic disorders but also informs the development of novel therapeutic strategies, ensuring better patient outcomes in the future.